Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
The immunomodulatory effects of adriamycin, a clinically used tumor antibiotic, were studied. A 5-day course of adriamycin therapy in mice led to a suppression of the primary but not of the secondary humoral response to sheep erythrocytes without significant alterations in peripheral blood leukocyte subsets or lymphocyte subpopulations in the spleen. The delayed type hypersensitivity (DTH) response to ovalbumin or alloantigens was not inhibited. Adriamycin-treated spleen cells were unable to stimulate an allogeneic mixed leukocyte reaction, which shows that antigen presentation is inhibited by this drug. Adriamycin-treated murine skin grafts show a prolonged survival after allotransplantation despite their unimpaired ability to induce DTH. The possible cellular mechanisms of these effects and clinical relevance of adriamycin are discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S0171-2985(89)80048-8 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!